Outlook Therapeutics, Inc. (OTLK)
NASDAQ: OTLK · Real-Time Price · USD
0.8150
-0.0280 (-3.32%)
Jun 2, 2026, 2:39 PM EDT - Market open
Outlook Therapeutics Stock Forecast
OTLK's stock price has decreased by -56.41% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 4 analysts polled by S&P Global, Outlook Therapeutics stock has a consensus rating of "Buy" and an average price target of $4.17. The average 1-year stock price forecast is 411.66% higher than the current stock price, while the lowest is $0.50 (-38.65%) and the highest is $6.00 (+636.20%).
Price Target: $4.17 (+411.66%)
Analyst Consensus: Buy
* Price targets were last updated on Apr 8, 2026.
Analyst Ratings
The average analyst rating for Outlook Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 3 | 2 | 2 | 1 | 1 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 4 | 4 | 3 | 3 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BTIG | BTIG | Hold Downgrades n/a | Hold | Downgrades | n/a | n/a | May 18, 2026 |
| H.C. Wainwright | H.C. Wainwright | Hold Reiterates $0.5 | Hold | Reiterates | $0.5 | -38.65% | Apr 8, 2026 |
| Ascendiant | Ascendiant | Buy Maintains $10 → $6 | Buy | Maintains | $10 → $6 | +636.20% | Mar 11, 2026 |
| Chardan Capital | Chardan Capital | Hold Maintains $3 → $1 | Hold | Maintains | $3 → $1 | +22.70% | Jan 2, 2026 |
Financial Forecast
Revenue This Year
21.64M
from 1.41M
Increased by 1,430.98%
Revenue Next Year
59.13M
from 21.64M
Increased by 173.23%
EPS This Year
-0.54
from -1.79
EPS Next Year
-0.28
from -0.54
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 48.3M | 139.3M | ||||||
| Avg | 21.6M | 59.1M | ||||||
| Low | 8.5M | 15.9M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 3,318.6% | 543.6% | ||||||
| Avg | 1,431.0% | 173.2% | ||||||
| Low | 498.1% | -26.3% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.44 | -0.15 | ||||||
| Avg | -0.54 | -0.28 | ||||||
| Low | -0.61 | -0.46 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Financial forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.